

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

IN RE: GENERIC PHARMACEUTICALS
PRICING ANTITRUST LITIGATION

MDL No. 2724
Case No. 2:16-MD-02724

THIS DOCUMENT RELATES TO:

Hon. Cynthia M. Rufe

ALL ACTIONS

**PRETRIAL ORDER NO. 81
(MYLAN RESPONSE TO PLAINTIFFS' INTERROGATORY NO. 2)**

AND NOW, this 28th day of March 2019, upon consideration of the recommendation of Special Master David H. Marion, and the parties' joint agreement to the terms stated below, it is hereby **ORDERED** that:

1. On or before **April 1, 2019**, Defendants Mylan Inc., Mylan Pharmaceuticals, Inc., Mylan N.V., and UDL Laboratories, Inc. (collectively, "Mylan") shall provide to Plaintiffs their supplemental responses to Interrogatory No. 2 of Plaintiffs' First Set of Interrogatories Directed to Defendants, dated April 24, 2018.

2. Mylan's supplemental responses shall identify, for each of the 22 employees identified in Appendix A of Mylan's Responses and Objections to Plaintiffs' First Set of Interrogatories Directed to Defendants, dated October 3, 2018, their:

- a. work-issued cellular telephone number(s) and associated carrier(s);
- b. personal cellular telephone number(s) and associated carrier(s), if used for any business purpose; and
- c. work landline telephone number(s).

3. Prior to April 1, 2019, Mylan shall provide to Plaintiffs the information required by Paragraph 2 above on a rolling basis, within a reasonable period of time after it becomes available to Mylan.

It is so **ORDERED**.

BY THE COURT:

/s/ Cynthia M. Rufe

CYNTHIA M. RUFÉ, J.